Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | PNP | P00491 | 7/20 | 0.61 |
| ▸ | HBB | P68871 | 2/20 | 0.61 |
| ▸ | BLM | P54132 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | EDNRA | P25101 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | POLG | P54098 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | VCP | P55072 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8444939 | 0.87 | MEN1 (0.80) | MEN1KMT2ATSHRPNPHBB | |
| SCHEMBL12786366 | 0.86 | PNP (0.70) | MEN1KMT2ATSHRPNPHBB | |
| SCHEMBL22875772 | 0.84 | MEN1 (0.64) | MEN1KMT2ATSHRPNPHBB | |
| SCHEMBL16082172 | 0.82 | PNP (0.72) | MEN1KMT2ATSHRPNPHBB | |
| SCHEMBL1177923 | 0.81 | MEN1 (0.60) | MEN1KMT2ATSHRPNPHBB | |
| SCHEMBL12786344 | 0.79 | PNP (0.77) | MEN1KMT2ATSHRPNPHBB | |
| SCHEMBL1177579 | 0.77 | MEN1 (0.68) | MEN1KMT2ATSHRPNPHBB | |
| SCHEMBL9021892 | 0.77 | TSHR (0.81) | MEN1KMT2ATSHRPNPHBB | |
| SCHEMBL10649363 | 0.77 | PNP (0.64) | MEN1KMT2ATSHRPNPHBB | |
| SCHEMBL7688901 | 0.77 | TK1 (0.70) | TSHRPNPHBBBLMUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123175-A1 | Compounds for Delivery of Therapeutic And Imaging Moieties to Nerve Cells | HILL G CRAIG (US) | 2013-05-16 | — | — | US | disclosed |
| US-8232251-B2 | Compounds for delivery of therapeutic and imaging moieties to nerve cells | MANZANITA PHARMACEUTICALS, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8138155-B2 | Compounds for intracellular delivery of therapeutic moieties to nerve cells | MANZANITA PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100266492-A1 | COMPOUNDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOIETIES TO NERVE CELLS | MANZANITA PHARMACEUTICALS, INC. | 2010-10-21 | — | — | US | disclosed |
| US-7718605-B2 | Compounds for intracellular delivery of therapeutic moieties to nerve cells | MANZANITA PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7678378-B2 | Compounds for intracellular delivery of therapeutic moieties to nerve cells | MANZANITA PHARMACEUTICALS, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20090286732-A1 | COMPOUNDS FOR DELIVERY OF THERAPEUTIC AND IMAGING MOIETIES TO NERVE CELLS | MANZANITA PHARMACEUTICALS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090124547-A1 | COMPOUNDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOIETIES TO NERVE CELLS | MANZANITA PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286732-A1 | COMPOUNDS FOR DELIVERY OF THERAPEUTIC AND IMAGING MOIETIES TO NERVE CELLS | CLTB, NMBR, L1CAM | MEN1 1420/4885KMT2A 4488/4885TSHR 1857/4885 |
| US-20130123175-A1 | Compounds for Delivery of Therapeutic And Imaging Moieties to Nerve Cells | CLTB, NMBR, L1CAM | MEN1 1420/4885KMT2A 4488/4885TSHR 1857/4885 |
| US-20090124547-A1 | COMPOUNDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOIETIES TO NERVE CELLS | CLTB, NMBR, PMP22 | MEN1 1755/4885KMT2A 4603/4885TSHR 413/4885 |
| US-20100266492-A1 | COMPOUNDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOIETIES TO NERVE CELLS | CLTB, NMBR, PMP22 | MEN1 1755/4885KMT2A 4603/4885TSHR 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.